Industry News

• MyoKardia announces proposed public offering of common stock  MyoKardia announced it has commenced a proposed underwritten public offering to sell $200,000,000 in shares of its common stock. MyoKardia expects to grant underwriters a 30-day option to purchase up to $30,000,000 in additional shares of common stock at the public offering price.
  March 25, 2019  
• Celgene submits application to FDA for Ozanimod for treatment of relapsing forms of MS  Celgene announced the Company has submitted a New Drug Application to the FDA for ozanimod for treatment of adults with relapsing forms of multiple sclerosis. Ozanimod is an oral, sphingosine 1-phosphate receptor modulator, which binds with high affinity selectively to S1P subtypes 1 and 5.
  March 25, 2019  
• NanoString announces closing of public offering of 5,175,000 shares of common stock  NanoString announced the closing of its underwritten public offering of 5,175,000 shares of its common stock at a price to the public of $23.00 per share. NanoString sold 3,175,000 shares of common stock, which includes the exercise in full by the underwriters of their option.
  March 25, 2019  
• BioXcel Therapeutics files clinical trial application for development of BXCL701 in tNEPC  BioXcel Therapeutics announced that it has filed a CTA with the U.K. health authorities for its lead immuno-oncology asset, BXCL701, an orally-available small molecule immune-modulator with dual mechanisms of action, in combination with pembrolizumab (Keytruda®), a checkpoint inhibitor, in tNEPC.
  March 25, 2019  
• European phase 3 trial of Aimmune Therapeutics’ AR101 meets primary endpoint  Aimmune Therapeutics announced that its phase 3 European clinical trial of AR101 for treatment of peanut allergy, known as ARTEMIS (AR101 Trial in Europe Measuring oral Immunotherapy Success), met its primary efficacy endpoint.
  March 25, 2019  
• Curis sells portion of Erivedge royalties to Oberland Capital for up to $135.7 million  Curis announced it has entered into an agreement with funds managed by Oberland Capital Management for up to $135.7 million in exchange for selling rights to a portion of royalty revenues on worldwide net sales of Erivedge.
  March 25, 2019  
• Onconova achieves over 75 percent of planned enrollment in pivotal phase 3 INSPIRE study  Onconova Therapeutics announced that it has surpassed the 75 percent enrollment milestone in its pivotal Phase 3 trial of rigosertib for the potential treatment of high-risk myelodysplastic syndromes (HR-MDS), a study known as INSPIRE.
  March 25, 2019  
• Aptose announces FDA allowance of Investigational New Drug Application for CG-806  Aptose announced the FDA completed their review of the Company’s IND submission for CG-806. Aptose has been granted IND allowance to initiate its Phase 1 clinical trial amulticenter, open label, dose-escalation study with expansions to assess the safety, tolerability, PK, and efficacy of CG-806.
  March 25, 2019  
• Thermo Fisher Scientific to acquire Brammer Bio for $1.7 billion in cash  Thermo Fisher Scientific announced they have entered into a definitive agreement whereby Thermo Fisher will acquire Brammer Bio for $1.7 billion in cash. Brammer Bio is a leading viral vector CDMO. The business has nearly 600 employees at primary locations in Massachusetts and Florida.
  March 24, 2019  
• Radius Health reports analysis from phase 3 ACTIVE trial and data from preclinical studies  Radius Health reported a post-hoc analysis of Phase 3 data from different patient populations included in the ACTIVE trial, and results from preclinical studies of abaloparatide and its effect on the development and growth of osteoclasts and on bone resorption.
  March 23, 2019  

   (next 10 articles)